Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PanCan Adaptive Clinical Trial Design

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 24, 2023 11:00am

214 Views

Post# 35512765

RE:RE:RE:PanCan Adaptive Clinical Trial Design

Interesting PanCan news feed:

https://www.curetoday.com/advocacy-groups/pancan

Also:

June 23, 2023 - The Food and Drug Administration (FDA) accepted a supplemental new drug application for Onivyde (irinotecan liposome injection) plus 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a potential first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, according to a press release from biopharmaceutical company, Ipsen. The review follows the results from the phase 3 NAPOLI trial, with Onivyde, administered twice in a month, versus those treated with nab-paclitaxel plus gemcitabine three times in a month.

Patients in the NALIRIFOX group had a median overall survival of 11.1 months, while those in the nab-paclitaxel and gemcitabine group had a median overall survival of 9.2 months, according to data from Ipsen originally presented at the January 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

The overall survival rates at 12 months were 45.6% and 39.5% for the NALIRIFOX and nab-paclitaxel and gemcitabine groups, respectively, and 26.2% and 19.3% at 18 months, Ipsen reported.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing